Obesity and anti-obesity medical and surgical management

27 Obesity and anti-obesity medical and surgical management



Case, Part 1


SB is a 48-year-old woman with type 2 diabetes mellitus, hypertension and hyperlipidemia who presents for weight loss. She reports struggling with weight since childhood but started gaining most significantly after her pregnancies, the last of which was at 28 years of age. She has tried several popular diets, including diet books and diet centres. She has also tried pills for weight loss, both ‘over the counter’ and ordered from television without success. Her current diet consists of a fast food sandwich and large diet soda in the mid-morning ‘on the run’, a piece of fruit with cheese and crackers at home in the mid-afternoon, and large meal with a meat, starch and vegetable for dinner with her family at home four nights a week and eating out the other three. In the evening, she snacks on a piece of cake, ice-cream or popcorn. She craves sweets, especially when stressed, and struggles with large portion sizes. She wants to avoid surgery if possible, but is open to hearing more about it. Her family history is significant for obesity in her mother and two of her three siblings, and hyperlipidaemia in her father and mother. She takes rosiglitazone 2 mg-metformin 1000 mg twice daily, insulin aspart 20 units with each meal, insulin glargine 45 units at bedtime, simvastatin 40 mg daily and lisinopril 20 mg twice daily. Pertinent physical exam findings include a weight of 126 kg, height of 162 cm, and body mass index (BMI) of 48.0 kg/m2. She has a waist of 42 inches. Her labs are unremarkable.




Medical Management


Pharmacotherapy and behaviour modification are the mainstays of non-surgical treatment of obesity, with behaviour modification being the oldest approach to weight loss. Most commonly applied as a program of decreased caloric intake coupled with increased physical activity, behavioural programs have been effective in curtailing weight gain and improving overweight and moderate obesity; however, these behaviour changes and resultant weight loss are difficult for patients to sustain. Additionally, the magnitude of weight loss only modestly improves the health of patients with morbid obesity, those in the greatest need for weight management. Behaviour modification programs usually result in loss of 5–10% of body weight over a 6-month period, but this loss is rarely maintained beyond 6–12 months. High protein, low-carbohydrate diets have had some recent popularity, but a study has shown that at 1 year there was little difference in outcome when such a diet was compared with a conventional diet. Very-low-calorie diets result in more rapid weight loss, but are not a long-term solution without significant, sustained behaviour modification. The risk of malnutrition and need for frequent changes to medication make medical supervision imperative, increasing the cost and decreasing the ease of access to this type of program.


Many pharmacological therapies exist for assistance with weight loss. The two medications approved for long-term use, orlistat (which inhibits dietary fat absorption) and sibutramine (which suppresses appetite), have been shown to produce modest weight loss. However, these medications have many unwanted side effects (such as diarrhoea with orlistat) that lead to non-compliance. When patients stop taking the medication, they often regain their lost weight. Finally, these medications are expensive and a considerable burden economically. Whether behaviour modification, pharmacotherapy or a combination of these approaches, the bottom-line issue with non-surgical weight management remains failure to achieve clinically significant weight loss for morbidly obese patients and failure to sustain weight loss for most patients. For many obese individuals, continued pursuit of these programs leads to recidivism, incremental weight gain, and the negative psychological and physiological consequences of repeated failures.


Recently, there has been interest in several putative gut hormones and their role in appetite, glucose metabolism and overall metabolism. Levels of glucagon-like peptide 1 (GLP-1), peptide YY (PYY), ghrelin, cholecystokinin (CCK), gastric inhibitory peptide (GIP), oxyntomodulin (OXW) and pancreatic polypeptide have all been shown to have anorexigenic or orexigenic effects, and some degree of change after various weight loss operations. This has renewed interest in the gut–brain axis and the regulating peptides, and their potential role in future weight management strategies.



May 30, 2016 | Posted by in GASTROENTEROLOGY | Comments Off on Obesity and anti-obesity medical and surgical management

Full access? Get Clinical Tree

Get Clinical Tree app for offline access